Diasome Pharmaceuticals
Signal active
Organization
Contact Information
Overview
Diasome Pharmaceuticals is a clinical stage diabetes therapeutics company that designs and develops insulin-based therapies. The company’s products include Oral HVD-I, a targeted oral insulin in a pill or gel cap dose form; HDV-I, an injectable short acting insulin; and HDV-B, an injectable basal long acting insulin. It develops products for patients suffering from Type 1 and Type 2 diabetes.
Diasome Pharmaceuticals was founded in 2004 and is based in Conshohocken, Pennsylvania.
About
Industries
Biotechnology, Life Science, Health Care, Medical, Therapeutics
Founded
2004
Employees
1-10
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Diasome Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Life Science, Health Care, Medical, Therapeutics sector. The company focuses on Biotechnology and has secured $12.9B in funding across 140 round(s). With a team of 1-10 employees, Diasome Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Debt Financing - Diasome Pharmaceuticals, raised $12.9M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
7
Investors
0
Lead Investors
0
Total Funding Amount
$92.0M
Details
1
Diasome Pharmaceuticals has raised a total of $92.0M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2008 | Early Stage Venture | 8.4M |
Investors
Diasome Pharmaceuticals is funded by 10 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Diasome Pharmaceuticals | - | FUNDING ROUND - Diasome Pharmaceuticals | 30.0M |
| Michele Ollier | - | FUNDING ROUND - Michele Ollier | 30.0M |
| Diasome Pharmaceuticals | - | FUNDING ROUND - Diasome Pharmaceuticals | 30.0M |
| Medicxi | - | FUNDING ROUND - Medicxi | 30.0M |
Recent Activity
There is no recent news or activity for this profile.